Effectiveness of human papillomavirus vaccine against incident and persistent infections among young girls: Results from a longitudinal Dutch cohort study

Vaccine

Volumn 33, Issue 23, 2015, Pages 2678-2683

  Mollers, Madelief ^a,b   King, Audrey J ^a   Knol, Mirjam J ^a   Scherpenisse, Mirte ^a,b   Meijer, Chris J L M ^b   Van Der Klis, Fiona R M ^a   De Melker, Hester E ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cervical cancer; HPV; Impact; Monitoring; Vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; INCIDENCE; INFECTION RATE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; PERSISTENT INFECTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; SEXUAL BEHAVIOR; VACCINATION; IMMUNOLOGY; NETHERLANDS; PAPILLOMAVIRUS INFECTIONS; TREATMENT OUTCOME; VAGINA; VIROLOGY;

ADOLESCENT; COHORT STUDIES; FEMALE; HUMANS; INCIDENCE; LONGITUDINAL STUDIES; NETHERLANDS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PROSPECTIVE STUDIES; SURVEYS AND QUESTIONNAIRES; TREATMENT OUTCOME; VAGINA;

EID: 84929044667     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.04.016     Document Type: Article

References (24)

1. Bouvard V., Baan R., Straif K., Grosse Y., Secretan B., El Ghissassi F., et al. A review of human carcinogens-Part B: Biological agents. Lancet Oncol 2009, 10:321-322.
2. De Martel C., Ferlay J., Franceschi S., Vignat J., Bray F., Forman D., et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012, 13:607-615. 10.1016/S1470-2045(12)70137-7.
3. Clifford G., Franceschi S., Diaz M., Muñoz N., Villa L.L. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006, 24(Suppl. 3: S3):26-34. 10.1016/j.vaccine.2006.05.026.
4. Castellsagué X., Muñoz N., Pitisuttithum P., Ferris D., Monsonego J., Ault K., et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011, 105:28-37. 10.1038/bjc.2011.185.
5. Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Farland S.M., Castellsagué X., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:89-99. 10.1016/S1470-2045(11)70286-8.
6. De Carvalho N., Teixeira J., Roteli-Martins C.M., Naud P., De Borba P., Zahaf T., et al. Sustained efficacy and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine up to 7.3 years in young adult women. Vaccine 2010, 28:6247-6255. 10.1016/j.vaccine.2010.07.007.
7. Wheeler C.M., Castellsague X., Garland S.M., Szarewski A., Paavonen J., Naud P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:100-110. 10.1016/S1470-2045(11)70287-X.
8. Malagon T., Drolet M., Boily M.C., Franco E.L., Jit M., Brisson J., et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:781-789. 10.1016/S1473-3099(12)70187-1.
9. van Lier E., Oomen P., Mulder M., Conyn-van Spaendonck M.A.E., Drijfhout I.H., de Hoogh P.A.A.M., et al. Vaccinatiegraad Rijksvaccinatieprogramma Nederland: Verslagjaar 2013. RIVM rapport nr. 150202001 2013, Rijksinstituut voor Volksgezondheid en Milieu, Bilthoven.
10. HealthCouncil The Netherlands: Vaccinatie tegen baarmoederhalskanker 2008.
11. Leval A., Herweijer E., Arnheim-Dahlstrom L., Walum H., Frans E., Sparén P., et al. Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability. J Infect Dis 2012, 206:860-866. 10.1093/infdis/jis405.
12. Ali H., Guy R.J., Wand H., Read T.R., Regan D.G., Grulich A.E., et al. Decline in in-patient treatments of genital warts among young Australians following the national HPV vaccination program. BMC Infect Dis 2013, 13:140. 10.1186/1471-2334-13-140.
13. Mollers M., Scherpenisse M., van der Klis F.R., King A.J., van Rossum T.G., van Logchem E.M., et al. Prevalence of genital HPV infections and HPV serology in adolescent girls, prior to vaccination. Cancer Epidemiol 2012, 36:519-524. 10.1016/j.canep.2012.07.006.
14. van Lier A., Oomen P., de Hoogh P., Drijfhout I., Elsinghorst B., Kemmeren J., et al. Praeventis, the immunisation register of the Netherlands: a tool to evaluate the National Immunisation Programme. Euro Surveill 2012, 17.
15. Kleter B., van Doorn L.J., ter Schegget J., Schrauwen L., van Krimpen K., Burger M., et al. Novel short-fragment PCR assay for highly sensitive broad-spectrum detection of anogenital human papillomaviruses. Am J Pathol 1998, 153:1731-1739.
16. Roteli-Martins C.M., Naud P., De Borba P., Teixera J.C., De Carvalho N.S., Zahaf T., et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immunother 2012, 8:390-397. 10.4161/hv.18865.
17. Plummer M., Vaccarella S., Franceschi S. Multiple human papillomavirus infections: the exception or the rule?. J Infect Dis 2011, 203:891-893. 10.1093/infdis/jiq146.
18. Ho G., Bierman R., Beardsley L., Chang C.J., Burk R.D. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 1998, 338:423-428.
19. Nielsen A., Kjaer S.K., Munk C., Osler M., Iftner.T. Persistence of high-risk human papillomavirus infection in a population-based cohort of Danish women. J Med Virol 2010, 82:616-623. 10.1002/jmv.21750.
20. Moscicki A., Hills N., Shiboski S., Powell K., Jay N., Hanson E., et al. Risks for incidence human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females. JAMA 2001, 285:2995-3002.
21. Burchell A.N., Tellier P.P., Hanley J., Coutlée F., Franco E.L. Influence of partner's infection status on prevalent human papillomavirus among persons with a new sex partner. Sex Transm Dis 2010, 37:34-40. 10.1097/OLQ.0b013e3181b35693.
22. Giuliano A.R., Harris R., Sedjo R.L., Baldwin S., Roe D., Papenfuss M.R., et al. Incidence, prevalence, and clearance of type-specific human papillomavirus infections: the Young Women's Health Study. J Infect Dis 2002, 186:462-469.
23. Vaccarella S., Herrero R., Snijders, Dai M, Thomas JO, Hieu NT et al.P.J. Smoking and human papillomavirus infection: pooled analysis of the International Agency for Research on Cancer HPV Prevalence Surveys. Int J Epidemiol 2008, 37:536-546. 10.1093/ije/dyn033.
24. Sopori M. Effects of cigarette smoke on the immune system. Nat Rev Immunol 2002, 2:372-377.